Multiple Sclerosis Disease Course and Classification
Ahmed Obeidat, MD, PhD, Stephen Krieger, MD, and Riley Bove, MD, discuss evolving understandings of continuum of MS and the mechanisms that cause relapse and the gradual accumulation of disability.
EP: 1.Multiple Sclerosis Disease Course and Classification
EP: 2.Defining the Utility of PIRA in Practice
EP: 3.Addressing Inflammation Upon the Diagnosis of MS
EP: 4.Multiple Sclerosis Onset and Age-Related Factors That Shape Treatment Approaches
EP: 5.Shared Decision-Making in Multiple Sclerosis Treatment
EP: 6.Clinical Trial Design and Personalized Medicine in Multiple Sclerosis
EP: 7.Customizing Treatment Approaches With High Efficacy Therapies
EP: 8.When to Stop Multiple Sclerosis Therapy
EP: 9.Immunological Phenotypes of Multiple Sclerosis and Patient Race
EP: 10.Pregnancy and Lactation in Multiple Sclerosis
This is a video synopsis/summary of a panel discussion involving Ahmed Obeidat, MD, PhD; Riley Bove, MD; Stephen Krieger, MD; and Erin Longbrake, MD, PhD.
The conversation revolves around early identification and treatment of multiple sclerosis (MS), focusing on 2 approaches: escalation or early use of high efficacy treatment. The participants also delve into patient types suitable for each approach and emphasize the significance of long-term data with NTCD-20 therapies in guiding treatment selection.
The speaker underscores the evolving understanding of MS, moving away from distinct subtypes to viewing it as a continuous spectrum with various mechanisms causing disability accumulation. He introduces the concept of a topographical model, emphasizing the need for more unified disease course understanding.
The speaker adds insights into age-related changes in MS, noting increased inflammation, relapses, and new lesions in younger individuals. As individuals age, inflammatory activity diminishes, but neurodegenerative changes become more prominent. This highlights the importance of considering age-related mechanisms in MS management.
Throughout the discussion, the experts stress the need for a nuanced approach to MS treatment, considering both inflammatory and neurodegenerative aspects across different stages of life. This comprehensive understanding is crucial for optimizing treatment strategies and improving long-term outcomes for patients with MS.
Video synopsis is AI-generated and reviewed by NeurologyLive editorial staff.
